An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours.
Phase of Trial: Phase 0
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs BI 754091 (Primary) ; BI 754111 (Primary)
- Indications Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 19 Feb 2018 New trial record